Join us for Office Hours with Dr. Mazen Hanna, leading cardiologist and Co-Director of the Cleveland Clinic’s Amyloidosis Program. This is your chance to ask questions and learn directly from a top expert in cardiac amyloidosis and heart failure care.

Dr. Mazen Hanna is a staff cardiologist at Cleveland Clinic, serving as Director of the Heart Failure ICU and Co‑Director of the Amyloidosis Program. He’s board-certified in cardiology, advanced heart failure, transplant, and specializes in cardiomyopathies and cardiac amyloidosis.

Regulatory approval is a crucial step in bringing a new medical product to market and ensuring that it is safe and effective for patients. The regulatory process can be complex and lengthy, involving multiple stages of review and evaluation by government agencies such as the Food and Drug Administration (FDA) in the United States. The process typically begins with preclinical studies, where the safety and efficacy of the product are evaluated in laboratory and animal studies. If the results are promising, the product may then advance to clinical trials, where it is tested in human subjects to further assess its safety and effectiveness. Once the clinical trial data is collected and analyzed, the sponsor of the product submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for review. The FDA conducts a thorough evaluation of the data, looking at factors such as the product's chemical composition, manufacturing process, labeling, and clinical trial results. During the review process, the FDA may request additional information or clarification from

Kathi Lewis is a dedicated patient advocate with the Amyloidosis Foundation, bringing her lived experience and deep empathy to every talk. She guides individuals coping with chronic disease through resilience-building tools, honest insights, and empowering community support.

Join Art Still, former Super Bowl champion, as he shares his journey of resilience, teamwork, and purpose beyond the game. Learn how his mission at still4life.org inspires strength and hope for patients and families facing life’s toughest challenges.”

Art Still, former NFL All-Pro and Kansas City Chiefs legend, now champions the amyloidosis community through his foundation Still 4 Life. After his own diagnosis with hereditary ATTR, he raises awareness, promotes early detection, and inspires patients to face challenges with strength and hope.

Living with a chronic disease often brings daily frustrations that can feel overwhelming. This session offers practical strategies, emotional tools, and peer support to help transform those challenges into strength, resilience, and a renewed sense of control.

Tom is a rare disease technology educator.  He advises patient organizations and pharmaceutical companies so that they can better serve the needs of their patient communities. Tom is living with Myasthenia Gravis and works closely with the MGFA (Myasthenia Gravis Foundation of America) and serves as a National Patient Ambassador.